Liaoning Cancer Hospital&Institute Trials

Liaoning Cancer Hospital&Institute	Welcome, Profile Billing Logout

99 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Wang, Chunyan

NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting

116

RoW

Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab

RemeGen Co., Ltd.

Cervical Cancer

06/27

12/27

TQB2450-II-14, NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting

RoW

TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Endometrial Cancer, Sarcoma of Uterus

06/24

12/24

NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn

177

RoW

Balstilimab, Balstilimab + Zalifrelimab

Agenus Inc., Betta Pharmaceuticals Co., Ltd.

Cervical Cancer

12/24

NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated

1/2

RoW

TQ-B3525 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

11/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06846099: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Recruiting

174

RoW

RP903

Risen (Suzhou) Pharma Tech Co., Ltd.

Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Solid Tumor Cancer

12/25

mLOWER, NCT02693496: Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research

Recruiting

N/A

10000

RoW

Installation or registration of smartphone application

Chinese Alliance Against Lung Cancer

Solitary Pulmonary Nodule

10/25

Zhang, Yu

NCT06506838: Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Recruiting

RoW

Anlotinib

Guangdong Provincial People's Hospital

Soft Tissue Sarcoma, Doxorubicin, Radiotherapy

07/27

07/28

PLG001, NCT05668871: A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder

Not yet recruiting

336

RoW

Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited)

Eastern Hepatobiliary Surgery Hospital

Polyps Gallbladder

08/24

11/24

NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed

750

RoW

ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273

Guangdong Raynovent Biotech Co., Ltd

Influenza A

04/23

05/23

NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

BRANT, NCT06037889: Efficacy and Safety of Tirofiban for Patients With BAD

Recruiting

516

RoW

Tirofiban, Tirofiban Hydrochloride and Sodium Chloride Injection, Aspirin tablet, Clopidogrel tablet

Peking Union Medical College Hospital, Pharmaron (Chengdu) Clinical Services Co., Ltd.

Branch Atheromatous Disease

07/25

10/25

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

NACI-CERV-003, NCT06288373: Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Recruiting

2/3

440

RoW

Camrelizumab, Cisplatin, Nab paclitaxel, Radical surgery, external beam radiation therapy (EBRT) + brachytherapy

Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Cancer Hospital of Guangxi Medical University

Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy

03/31

TQB3616-ALTN-II-01, NCT04924192: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Recruiting

126

RoW

TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Lung Carcinoma

05/23

12/23

NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated

RoW

Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine

Jiangsu Simcere Pharmaceutical Co., Ltd.

Advanced Solid Tumor

07/23

NCT05765825: Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Recruiting

RoW

serplulimab, HLX10, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection, Etoposide, Etoposide injection, Thoracic radiation therapy (TRT), low-dose radiotherapy

Sichuan University

Extensive-stage Small-cell Lung Cancer

06/24

12/25

Guard-05, NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting

RoW

Efbemalenograstim Alfa

Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Ovarian Cancer, Cervical Cancer

06/26

12/26

NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting

RoW

B013, Paclitaxel, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Platinum-resistant Recurrent Ovarian Cancer

12/26

NACI-CERV-002, NCT06288360: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting

RoW

Camrelizumab, SHR-1210, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, radical surgery

Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University

Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy

12/25

12/30

NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting

460

RoW

HS-20089

Hansoh BioMedical R&D Company

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

12/25

12/27

NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

	Efficacy data from trial in combination with azacitidine for MDS
	Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
	Data from a study in combination with azacitidine for MDS at ESMO 2022
	Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022

Completed

1/2

105

RoW

TJ011133

TJ Biopharma Co., Ltd.

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)

12/23

NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting

1/2

160

RoW

YK-029A

Suzhou Puhe Pharmaceutical Technology Co., LTD

Treatment, Treatment Side Effects

12/23

05/24

NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

1/2

RoW

BG1805

Guangzhou Bio-gene Technology Co., Ltd

Leukemia, Myeloid, Acute

03/25

07/25

NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Recruiting

1/2

168

RoW

SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Non-small Cell Lung Cancer

06/26

NCT05788159: An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.

Not yet recruiting

RoW

Lacosamide Tablets, Lacosamide extended release tablets

Overseas Pharmaceuticals, Ltd., Beijing Capton Pharmaceutical Technology Development Co., LTD

Epilepsy

06/23

07/23

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT06412458: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Not yet recruiting

RoW

IM83 CAR-T Cells

Beijing Immunochina Medical Science & Technology Co., Ltd., Guangdong Provincial People's Hospital

Refractory Osteosarcoma, Recurrent Osteosarcoma

06/25

06/26

NCT06662760: Clinical Trial of TQB3002 in Patients With Advanced Cancers

Recruiting

120

RoW

TQB3002 Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Cancer

10/25

10/26

NCT05151133: Clinical Study of Allergic Rhinitis Therapy by Stem Cells

Recruiting

RoW

Low dose UCMSCs, Moderate dose UCMSCs, High dose UCMSCs

Yantai Yuhuangding Hospital

Allergic Rhinitis

12/24

APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting

102

RoW

APG-115, Azacitidine, Cytarabine

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

12/25

NCT04173832: Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Recruiting

N/A

100

RoW

Tianqi Pingchan Granule Combined With Amantadine, Placebo Combined With Amantadine

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Wenzhou Central Hospital, The Affiliated Hospital of Qingdao University, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, The Affiliated Hospital of Xuzhou Medical University

L-DOPA-Induced Dyskinesia

12/20

12/21

NCT05233917: Effects of Olive Oil and MLCT on Glycolipid Homeostasis in Patients With Metabolic Syndrome

Completed

N/A

240

RoW

Olive oil use, MLCT oil use

Zhejiang University

Hyperlipidaemia, Metabolic Syndrome

12/23

EBPS, NCT04809025: Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Recruiting

N/A

510

RoW

endoscopy, Surgery

Fudan University

Stomach Neoplasms, Endoscopy, Biopsy, Pathology

04/23

04/24

PNFS, NCT05247632: Precision Nutrition and Food Safety for Dietary Prevention of Chronic Disease Study

Active, not recruiting

N/A

2290

RoW

Zhejiang University, Lanxi Red Cross Hospital, Lanxi Hospital of Traditional Chinese Medicine

Chronic Diseases

05/24

07/28

NCT06039735: Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

Recruiting

N/A

RoW

Chemotherapy and/or autologous hematopoietic stem cell transplantation

Qilu Hospital of Shandong University

Multiple Myeloma

11/23

12/28

NCT06512207: A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Recruiting

N/A

RoW

Leuprorelin acetate + Sintilimab, Leuprolide, Sintilimab, Anti-PD-1 monoclonal

Jinzhou Medical University, The First Affiliated Hospital of Zhengzhou University

NSCLC, Stage III, NSCLC, Stage IV

12/25

06/26

PROBEAT, NCT05179447: PROfiling Based Endometrial Cancer Adjuvant Therapy

Recruiting

N/A

590

RoW

Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy

Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital

Endometrial Cancer Stage I, Endometrial Cancer Stage II

12/26

01/27

NCT06276309: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Recruiting

N/A

300

RoW

Fujian Maternity and Child Health Hospital

Neuroendocrine Neoplasm, China, Women, Cervical Cancer, Cervical Lesion

12/24

02/25

NCT06717178: Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China

Recruiting

N/A

322

RoW

Chemotherapy

RenJi Hospital

Cancer, Cancer-related Problem/Condition

12/25

NCT05932576: A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women

Recruiting

N/A

12000

RoW

Fujian Maternity and Child Health Hospital

Human Papillomavirus Vaccines, Efficacy, Self, Adverse Effect, China, Woman

12/24

NCT05932563: Study on the Epidemiological Characteristics of Female HPV Vaccination in China

Recruiting

N/A

1700

RoW

Fujian Maternity and Child Health Hospital

Human Papillomavirus Vaccines, Adverse Effect, Epidemiology, China, Woman

12/24

Zhang, Jingdong

NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting

351

RoW

RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan

RemeGen Co., Ltd.

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

12/24

06/25

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

	NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
	Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification

Recruiting

RoW

Infigratinib, BGJ398

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor

12/22

12/23

NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

RoW

Anti-PD-1 antibody, XELOX

China Medical University, China

Gastric or Gastroesophageal Junction Adenocarcinoma, AFP

09/21

NCT03484195: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil

China Medical University, China

Colonic Neoplasms, Drug Therapy

10/21

NCT03484221: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil, Short-Course Radiation Therapy(5Gy*5), XELOX, Capecitabine

China Medical University, China

Rectal Neoplasms, Drug Therapy, Radiation

10/21

04/22

NCT03487939: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil

China Medical University, China

Colorectal Neoplasms, Drug Therapy

10/21

TRAP study, NCT04483219: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Recruiting

RoW

TKI ± anti-PD-1 antibody

China Medical University, China

MSS, pMMR, Metastatic Colorectal Adenocarcinoma

07/22

NCT04006821: PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Recruiting

RoW

PD-1 antibody, Camrelizumab, Apatinib mesylate

China Medical University, China

Gastric Cancer, AFP

08/22

MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

12/22

08/23

NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

Recruiting

RoW

FOLFOX/FOLFIRI

China Medical University, China

Unresectable or Metastatic Colorectal Cancer

12/23

12/24

NCT05127759: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Active, not recruiting

RoW

HLX208, BRAF V600E inhibitor

Shanghai Henlius Biotech

Metastatic Colorectal Cancer, mCRC

01/24

06/25

NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting

103

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

01/25

NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Recruiting

108

RoW

HLX10

Shanghai Henlius Biotech

MSI-H Solid Malignant Tumor

05/24

06/26

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

AK104-IIT-025, NCT06118645: Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Not yet recruiting

cadonilimab combined +paclitaxel (albumin-bound)

China Medical University, China

Gastric Adenocarcinoma

09/24

08/26

NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Recruiting

RoW

TT-00420 (tinengotinib)

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma Metastatic

06/25

10/25

NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Intrahepatic Cholangiocarcinoma (ICC)

05/26

12/26

TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

02/25

05/25

NCT06500676: A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting

1/2

390

RoW

GFH375

Genfleet Therapeutics (Shanghai) Inc.

KRAS G12D Mutations, Advanced Solid Tumors

07/28

12/28

NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Recruiting

RoW

LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus

Taizhou HoudeAoke Biomedical Co., Ltd.

Digestive System Neoplasms

06/21

06/22

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

CSG-1906-101, NCT05857332: SG1906 for CLDN18.2-Positive Solid Tumors

Recruiting

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

CLINCH, NCT05718895: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Recruiting

156

RoW

ATG-022

Antengene Biologics Limited

Advanced/Metastatic Solid Tumors

06/26

Wang, Danbo

innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting

502

Europe, Canada, Japan, US, RoW

tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed

Seagen, a wholly owned subsidiary of Pfizer, Genmab

Cervical Cancer

07/23

05/26

TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting

420

RoW

Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Endometrial Cancer

12/27

06/29

NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting

498

RoW

QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin

Qilu Pharmaceutical Co., Ltd.

METASTATIC CERVICAL CANCER

09/24

07/25

TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting

196

RoW

TQB2450, Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Endometrial Cancer

12/21

04/22

PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed

150

US, RoW

Paclitaxel, Afuresertib, LAE002

Laekna Limited

Platinum-resistant Ovarian Cancer

07/23

06/24

NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting

108

RoW

Envafolimab+Lenvatinib, Envafolimab

3D Medicines (Sichuan) Co., Ltd.

Advanced Endometrial Cancer

03/25

10/25

NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting

RoW

B013, Paclitaxel, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Platinum-resistant Recurrent Ovarian Cancer

12/26

AK104-218, NCT05932212: AK104 for Recurrent or Metastatic Vulvar Cancer

Recruiting

RoW

AK104, Cadonilimab, AK104+ Paclitaxel+Cisplatin or Carboplatin

Akeso

Vulvar Cancer

12/25

NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting

1/2

RoW

Bevacizumab； HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Recurrent Ovarian Cancer

10/25

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

NCT05773820: A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

Recruiting

1/2

210

RoW

WJB001

Wigen Biomedicine Technology (Shanghai) Co., Ltd., Sponsor GmbH

Advanced Solid Tumors

04/26

05/26

BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting

216

RoW

BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection

Bio-Thera Solutions

Advanced Solid Tumors

12/24

12/25

NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting

153

RoW

HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Advanced Solid Tumors

12/24

Zhang, Xiaojing

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting

1/2

254

US, RoW

HH2853 Tablets

Haihe Biopharma Co., Ltd.

FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor

12/25

NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting

1/2

RoW

SPH4336, Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

05/25

12/25

Dai, Chaoliu

NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting

480

RoW

Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Hepatocellular Carcinoma

08/24

12/26

NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Intrahepatic Cholangiocarcinoma (ICC)

05/26

12/26

CRGGC, NCT04140552: Chinese Research Group of Gallbladder Cancer

Recruiting

N/A

10000

RoW

Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital

Gallbladder Neoplasms

12/22

12/25

Zheng, Zhichao

DRAGON - IV, NCT04208347: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting

2/3

580

RoW

Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg

Ruijin Hospital

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

12/24

08/25

NCT04936178: A Study of NB003 in Patients with Advanced Malignancies

Recruiting

258

Europe, US, RoW

NB003 tablets

Ningbo Newbay Technology Development Co., Ltd

Advanced Solid Tumor

07/25

12/25

Li, Xianan

TQB2916-AK105-II-01, NCT06500091: TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Not yet recruiting

RoW

TQB2916 injection + doxorubicin hydrochloride for injection, TQB2916 injection+penpulimab injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Soft Tissue Sarcoma, Melanoma

06/26

12/26

NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting

120

RoW

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Melanoma

06/25

07/26

NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Recruiting

RoW

TK216+Vincristin

Shanghai Pharmaceuticals Holding Co., Ltd

Sarcoma, Ewing

09/25

12/25

ARTEMIS-002, NCT05830123: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting

170

RoW

HS-20093

Hansoh BioMedical R&D Company

Osteosarcoma, Sarcoma

12/25

12/27

NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting

1/2

254

US, RoW

HH2853 Tablets

Haihe Biopharma Co., Ltd.

FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor

12/25

TQB2928-ALTN-Ib-01, NCT06438783: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Recruiting

RoW

1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Osteosarcoma, Other Solid Tumors

10/25

02/26

NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Recruiting

316

RoW

HSK42360

Haisco Pharmaceutical Group Co., Ltd.

Solid Tumors

08/26

07/27

Zhu, Xia

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Wang, Chunyan

NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting

116

RoW

Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab

RemeGen Co., Ltd.

Cervical Cancer

06/27

12/27

TQB2450-II-14, NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting

RoW

TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Endometrial Cancer, Sarcoma of Uterus

06/24

12/24

NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn

177

RoW

Balstilimab, Balstilimab + Zalifrelimab

Agenus Inc., Betta Pharmaceuticals Co., Ltd.

Cervical Cancer

12/24

NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated

1/2

RoW

TQ-B3525 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

11/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06846099: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Recruiting

174

RoW

RP903

Risen (Suzhou) Pharma Tech Co., Ltd.

Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Solid Tumor Cancer

12/25

mLOWER, NCT02693496: Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research

Recruiting

N/A

10000

RoW

Installation or registration of smartphone application

Chinese Alliance Against Lung Cancer

Solitary Pulmonary Nodule

10/25

Zhang, Yu

NCT06506838: Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Recruiting

RoW

Anlotinib

Guangdong Provincial People's Hospital

Soft Tissue Sarcoma, Doxorubicin, Radiotherapy

07/27

07/28

PLG001, NCT05668871: A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder

Not yet recruiting

336

RoW

Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited)

Eastern Hepatobiliary Surgery Hospital

Polyps Gallbladder

08/24

11/24

NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed

750

RoW

ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273

Guangdong Raynovent Biotech Co., Ltd

Influenza A

04/23

05/23

NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

BRANT, NCT06037889: Efficacy and Safety of Tirofiban for Patients With BAD

Recruiting

516

RoW

Tirofiban, Tirofiban Hydrochloride and Sodium Chloride Injection, Aspirin tablet, Clopidogrel tablet

Peking Union Medical College Hospital, Pharmaron (Chengdu) Clinical Services Co., Ltd.

Branch Atheromatous Disease

07/25

10/25

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

NACI-CERV-003, NCT06288373: Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Recruiting

2/3

440

RoW

Camrelizumab, Cisplatin, Nab paclitaxel, Radical surgery, external beam radiation therapy (EBRT) + brachytherapy

Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy

03/31

Recruiting

126

RoW

TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Lung Carcinoma

05/23

12/23

NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated

RoW

Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine

Jiangsu Simcere Pharmaceutical Co., Ltd.

Advanced Solid Tumor

07/23

NCT05765825: Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Recruiting

RoW

serplulimab, HLX10, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection, Etoposide, Etoposide injection, Thoracic radiation therapy (TRT), low-dose radiotherapy

Sichuan University

Extensive-stage Small-cell Lung Cancer

06/24

12/25

Guard-05, NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting

RoW

Efbemalenograstim Alfa

Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Ovarian Cancer, Cervical Cancer

06/26

12/26

NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting

RoW

B013, Paclitaxel, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Platinum-resistant Recurrent Ovarian Cancer

12/26

NACI-CERV-002, NCT06288360: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting

RoW

Camrelizumab, SHR-1210, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, radical surgery

Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University

Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy

12/25

12/30

NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting

460

RoW

HS-20089

Hansoh BioMedical R&D Company

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

12/25

12/27

	Efficacy data from trial in combination with azacitidine for MDS
	Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
	Data from a study in combination with azacitidine for MDS at ESMO 2022
	Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022

Completed

1/2

105

RoW

TJ011133

TJ Biopharma Co., Ltd.

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)

12/23

NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting

1/2

160

RoW

YK-029A

Suzhou Puhe Pharmaceutical Technology Co., LTD

Treatment, Treatment Side Effects

12/23

05/24

NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

1/2

RoW

BG1805

Guangzhou Bio-gene Technology Co., Ltd

Leukemia, Myeloid, Acute

03/25

07/25

NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Recruiting

1/2

168

RoW

SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Non-small Cell Lung Cancer

06/26

Not yet recruiting

RoW

Lacosamide Tablets, Lacosamide extended release tablets

Overseas Pharmaceuticals, Ltd., Beijing Capton Pharmaceutical Technology Development Co., LTD

Epilepsy

06/23

07/23

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT06412458: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Not yet recruiting

RoW

IM83 CAR-T Cells

Beijing Immunochina Medical Science & Technology Co., Ltd., Guangdong Provincial People's Hospital

Refractory Osteosarcoma, Recurrent Osteosarcoma

06/25

06/26

NCT06662760: Clinical Trial of TQB3002 in Patients With Advanced Cancers

Recruiting

120

RoW

TQB3002 Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Cancer

10/25

10/26

NCT05151133: Clinical Study of Allergic Rhinitis Therapy by Stem Cells

Recruiting

RoW

Low dose UCMSCs, Moderate dose UCMSCs, High dose UCMSCs

Yantai Yuhuangding Hospital

Allergic Rhinitis

12/24

APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting

102

RoW

APG-115, Azacitidine, Cytarabine

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

12/25

NCT04173832: Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Recruiting

N/A

100

RoW

Tianqi Pingchan Granule Combined With Amantadine, Placebo Combined With Amantadine

L-DOPA-Induced Dyskinesia

12/20

12/21

NCT05233917: Effects of Olive Oil and MLCT on Glycolipid Homeostasis in Patients With Metabolic Syndrome

Completed

N/A

240

RoW

Olive oil use, MLCT oil use

Zhejiang University

Hyperlipidaemia, Metabolic Syndrome

12/23

EBPS, NCT04809025: Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Recruiting

N/A

510

RoW

endoscopy, Surgery

Fudan University

Stomach Neoplasms, Endoscopy, Biopsy, Pathology

04/23

04/24

PNFS, NCT05247632: Precision Nutrition and Food Safety for Dietary Prevention of Chronic Disease Study

Active, not recruiting

N/A

2290

RoW

Zhejiang University, Lanxi Red Cross Hospital, Lanxi Hospital of Traditional Chinese Medicine

Chronic Diseases

05/24

07/28

NCT06039735: Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

Recruiting

N/A

RoW

Chemotherapy and/or autologous hematopoietic stem cell transplantation

Qilu Hospital of Shandong University

Multiple Myeloma

11/23

12/28

NCT06512207: A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Recruiting

N/A

RoW

Leuprorelin acetate + Sintilimab, Leuprolide, Sintilimab, Anti-PD-1 monoclonal

Jinzhou Medical University, The First Affiliated Hospital of Zhengzhou University

NSCLC, Stage III, NSCLC, Stage IV

12/25

06/26

PROBEAT, NCT05179447: PROfiling Based Endometrial Cancer Adjuvant Therapy

Recruiting

N/A

590

RoW

Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy

Endometrial Cancer Stage I, Endometrial Cancer Stage II

12/26

01/27

NCT06276309: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Recruiting

N/A

300

RoW

Fujian Maternity and Child Health Hospital

Neuroendocrine Neoplasm, China, Women, Cervical Cancer, Cervical Lesion

12/24

02/25

NCT06717178: Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China

Recruiting

N/A

322

RoW

Chemotherapy

RenJi Hospital

Cancer, Cancer-related Problem/Condition

12/25

NCT05932576: A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women

Recruiting

N/A

12000

RoW

Fujian Maternity and Child Health Hospital

Human Papillomavirus Vaccines, Efficacy, Self, Adverse Effect, China, Woman

12/24

NCT05932563: Study on the Epidemiological Characteristics of Female HPV Vaccination in China

Recruiting

N/A

1700

RoW

Fujian Maternity and Child Health Hospital

Human Papillomavirus Vaccines, Adverse Effect, Epidemiology, China, Woman

12/24

Zhang, Jingdong

NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting

351

RoW

RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan

RemeGen Co., Ltd.

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

12/24

06/25

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

	NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
	Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification

Recruiting

RoW

Infigratinib, BGJ398

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor

12/22

12/23

NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

RoW

Anti-PD-1 antibody, XELOX

China Medical University, China

Gastric or Gastroesophageal Junction Adenocarcinoma, AFP

09/21

NCT03484195: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil

China Medical University, China

Colonic Neoplasms, Drug Therapy

10/21

NCT03484221: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil, Short-Course Radiation Therapy(5Gy*5), XELOX, Capecitabine

China Medical University, China

Rectal Neoplasms, Drug Therapy, Radiation

10/21

04/22

NCT03487939: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

Recruiting

RoW

FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil

China Medical University, China

Colorectal Neoplasms, Drug Therapy

10/21

TRAP study, NCT04483219: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Recruiting

RoW

TKI ± anti-PD-1 antibody

China Medical University, China

MSS, pMMR, Metastatic Colorectal Adenocarcinoma

07/22

NCT04006821: PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Recruiting

RoW

PD-1 antibody, Camrelizumab, Apatinib mesylate

China Medical University, China

Gastric Cancer, AFP

08/22

MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

12/22

08/23

NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

Recruiting

RoW

FOLFOX/FOLFIRI

China Medical University, China

Unresectable or Metastatic Colorectal Cancer

12/23

12/24

NCT05127759: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Active, not recruiting

RoW

HLX208, BRAF V600E inhibitor

Shanghai Henlius Biotech

Metastatic Colorectal Cancer, mCRC

01/24

06/25

Active, not recruiting

103

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

01/25

NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Recruiting

108

RoW

HLX10

Shanghai Henlius Biotech

MSI-H Solid Malignant Tumor

05/24

06/26

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

AK104-IIT-025, NCT06118645: Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Not yet recruiting

cadonilimab combined +paclitaxel (albumin-bound)

China Medical University, China

Gastric Adenocarcinoma

09/24

08/26

NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Recruiting

RoW

TT-00420 (tinengotinib)

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma Metastatic

06/25

10/25

NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Intrahepatic Cholangiocarcinoma (ICC)

05/26

12/26

TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

02/25

05/25

NCT06500676: A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting

1/2

390

RoW

GFH375

Genfleet Therapeutics (Shanghai) Inc.

KRAS G12D Mutations, Advanced Solid Tumors

07/28

12/28

NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Recruiting

RoW

LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus

Taizhou HoudeAoke Biomedical Co., Ltd.

Digestive System Neoplasms

06/21

06/22

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

CSG-1906-101, NCT05857332: SG1906 for CLDN18.2-Positive Solid Tumors

Recruiting

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

CLINCH, NCT05718895: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Recruiting

156

RoW

ATG-022

Antengene Biologics Limited

Advanced/Metastatic Solid Tumors

06/26

Wang, Danbo

innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting

502

Europe, Canada, Japan, US, RoW

tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed

Seagen, a wholly owned subsidiary of Pfizer, Genmab

Cervical Cancer

07/23

05/26

TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting

420

RoW

Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Endometrial Cancer

12/27

06/29

NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting

498

RoW

QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin

Qilu Pharmaceutical Co., Ltd.

METASTATIC CERVICAL CANCER

09/24

07/25

TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting

196

RoW

TQB2450, Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Endometrial Cancer

12/21

04/22

PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed

150

US, RoW

Paclitaxel, Afuresertib, LAE002

Laekna Limited

Platinum-resistant Ovarian Cancer

07/23

06/24

NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting

108

RoW

Envafolimab+Lenvatinib, Envafolimab

3D Medicines (Sichuan) Co., Ltd.

Advanced Endometrial Cancer

03/25

10/25

NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting

RoW

B013, Paclitaxel, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Platinum-resistant Recurrent Ovarian Cancer

12/26

AK104-218, NCT05932212: AK104 for Recurrent or Metastatic Vulvar Cancer

Recruiting

RoW

AK104, Cadonilimab, AK104+ Paclitaxel+Cisplatin or Carboplatin

Akeso

Vulvar Cancer

12/25

NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting

1/2

RoW

Bevacizumab； HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Recurrent Ovarian Cancer

10/25

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

08/25

07/26

NCT05773820: A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

Recruiting

1/2

210

RoW

WJB001

Wigen Biomedicine Technology (Shanghai) Co., Ltd., Sponsor GmbH

Advanced Solid Tumors

04/26

05/26

BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting

216

RoW

BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection

Bio-Thera Solutions

Advanced Solid Tumors

12/24

12/25

NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting

153

RoW

HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Advanced Solid Tumors

12/24

Zhang, Xiaojing

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting

1/2

254

US, RoW

HH2853 Tablets

Haihe Biopharma Co., Ltd.

FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor

12/25

NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting

1/2

RoW

SPH4336, Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

05/25

12/25

Dai, Chaoliu

NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting

480

RoW

Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Hepatocellular Carcinoma

08/24

12/26

NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Intrahepatic Cholangiocarcinoma (ICC)

05/26

12/26

CRGGC, NCT04140552: Chinese Research Group of Gallbladder Cancer

Recruiting

N/A

10000

RoW

Gallbladder Neoplasms

12/22

12/25

Zheng, Zhichao

DRAGON - IV, NCT04208347: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting

2/3

580

RoW

Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg

Ruijin Hospital

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

12/24

08/25

NCT04936178: A Study of NB003 in Patients with Advanced Malignancies

Recruiting

258

Europe, US, RoW

NB003 tablets

Ningbo Newbay Technology Development Co., Ltd

Advanced Solid Tumor

07/25

12/25

Li, Xianan

TQB2916-AK105-II-01, NCT06500091: TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Not yet recruiting

RoW

TQB2916 injection + doxorubicin hydrochloride for injection, TQB2916 injection+penpulimab injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Soft Tissue Sarcoma, Melanoma

06/26

12/26

NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting

120

RoW

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Melanoma

06/25

07/26

NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Recruiting

RoW

TK216+Vincristin

Shanghai Pharmaceuticals Holding Co., Ltd

Sarcoma, Ewing

09/25

12/25

ARTEMIS-002, NCT05830123: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting

170

RoW

HS-20093

Hansoh BioMedical R&D Company

Osteosarcoma, Sarcoma

12/25

12/27

NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting

1/2

254

US, RoW

HH2853 Tablets

Haihe Biopharma Co., Ltd.

FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor

12/25

TQB2928-ALTN-Ib-01, NCT06438783: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Recruiting

RoW

1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Osteosarcoma, Other Solid Tumors

10/25

02/26

NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Recruiting

316

RoW

HSK42360

Haisco Pharmaceutical Group Co., Ltd.

Solid Tumors

08/26

07/27

Zhu, Xia

MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting

Europe, Canada, US, RoW

Pimicotinib(ABSK021), Placebo

Abbisko Therapeutics Co, Ltd

Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

05/26

06/28

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites